Home › Funds › AdvisorShares Psychedelics ETF
Fund family: AdvisorShares Trust · Filed by AdvisorShares Trust (CIK 1408970) · SEC series S000072085
Ticker: PSIL (C000227806)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 200 with, 4 against, 0 abstentions (not counted as with management); 9 items carried no recommendation. Shareholder proposals: 1 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other AdvisorShares Trust funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 123 | 2 |
| Audit-related | 28 | 0 |
| Capital Structure | 16 | 0 |
| Compensation | 15 | 0 |
| Say-on-Pay | 14 | 0 |
| Corporate Governance | 12 | 2 |
| Extraordinary Transactions | 4 | 0 |
| Other | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Compass Pathways Plc | May 27, 2026 | $2M | 10 | 0 |
| Neurocrine Biosciences, Inc. | May 27, 2026 | $1M | 6 | 0 |
| AbbVie Inc. | May 8, 2026 | $1M | 8 | 1 |
| Johnson & Johnson | April 23, 2026 | $955,434 | 15 | 1 |
| Neuronetics, Inc. | May 28, 2026 | $393,354 | 10 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| December 12, 2025 | Neuphoria Therapeutics Inc. | Election of two Class I directors to serve for a three-year term of office expiring at the 2028 Annual Meeting of Shareholders. While you may mark instructions with respect to any or all of the nominees, you may mark "FOR" only in respect of two nominees in total. You are permitted to vote for fewer than two nominees. If you vote "FOR" in respect of fewer than two nominees, your shares will only be voted "FOR" in respect of the nominee you have marked. If you vote "FOR" in respect of more than two nominees, your votes on Proposal 1 regarding director elections will be invalid or will not be counted. If you sign and return your proxy card and do not specify how you want your shares to be voted, they will be voted "FOR" in respect of all the Company nominees. LYNX1 Nominees: Stephen Doberstein Shareholder proposal | Withhold | For |
| December 12, 2025 | Neuphoria Therapeutics Inc. | Election of two Class I directors to serve for a three-year term of office expiring at the 2028 Annual Meeting of Shareholders. While you may mark instructions with respect to any or all of the nominees, you may mark "FOR" only in respect of two nominees in total. You are permitted to vote for fewer than two nominees. If you vote "FOR" in respect of fewer than two nominees, your shares will only be voted "FOR" in respect of the nominee you have marked. If you vote "FOR" in respect of more than two nominees, your votes on Proposal 1 regarding director elections will be invalid or will not be counted. If you sign and return your proxy card and do not specify how you want your shares to be voted, they will be voted "FOR" in respect of all the Company nominees. LYNX1 Nominees: Kimberly Smith Shareholder proposal | Withhold | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
214 ballot items at 28 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, AdvisorShares Psychedelics ETF (PSIL) voted at 28 shareholder meetings of 25 companies, on 214 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 4 times. Its most frequent area of disagreement was director elections (2 of its votes against management). It voted on 6 shareholder proposals. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.